Teva Pharmaceutical Industries Ltd
Strategic Management Major Assignment
-Analysis on Teva Pharmaceutical Industries Ltd.
1. Introduction
1.1 Teva at a Glance
Founded in 1901, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) was formed by three young pharmacists in Jerusalem, Israel. Teva is a leader in the global pharmaceutical industry: one out of every seven prescriptions in the US and one out of every six prescriptions in the UK is filled with a Teva product. Ranking among the top 10 pharmaceutical companies in the world, it specializes in generic and specialty drugs and is the largest global producer of generic medicines. Headquartered in Israel, Teva has a global product portfolio of more than 1,000 molecules, sold in more than 100 countries. It operates in 60 countries worldwide and has approximately 55,000 employees and net revenues of $20.3 billion in 2013.
1.2 Business Segments
Teva operates through 3 segments: generics, specialty and others. The generics segment provides chemical and therapeutic equivalents of originator medicines in tablets, capsules, creams, liquid, ointments, injectables, and inhalants. This segment generated revenues of $9.9 billion in 2013, making up 49% of Teva’s revenues, among which 42% were attributable to the US market, 35% were from Europe and 23% were from the rest of the world.
The specialty segment is the second largest and accounts for about 41% of the total revenue of Teva in 2013. The specialty segment focuses on areas including medicines for respiratory and CNS disorders, oncology and women’s health. CNS’s leading brand is Copaxone, in 2013, which generated $4.3 billion in sales, making up 21% of the company’s sales and constituting 42% of the company’s earnings.
The others segment accounts for 10% of sales. In this segment, Teva has built a unique relationship with P&G and operates in 65 markets outside North America, selling cough/cold and allergy, digestion, vitamins, minerals and supplements, and painkillers.
1.3 Current Situation and
-Analysis on Teva Pharmaceutical Industries Ltd.
1. Introduction
1.1 Teva at a Glance
Founded in 1901, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) was formed by three young pharmacists in Jerusalem, Israel. Teva is a leader in the global pharmaceutical industry: one out of every seven prescriptions in the US and one out of every six prescriptions in the UK is filled with a Teva product. Ranking among the top 10 pharmaceutical companies in the world, it specializes in generic and specialty drugs and is the largest global producer of generic medicines. Headquartered in Israel, Teva has a global product portfolio of more than 1,000 molecules, sold in more than 100 countries. It operates in 60 countries worldwide and has approximately 55,000 employees and net revenues of $20.3 billion in 2013.
1.2 Business Segments
Teva operates through 3 segments: generics, specialty and others. The generics segment provides chemical and therapeutic equivalents of originator medicines in tablets, capsules, creams, liquid, ointments, injectables, and inhalants. This segment generated revenues of $9.9 billion in 2013, making up 49% of Teva’s revenues, among which 42% were attributable to the US market, 35% were from Europe and 23% were from the rest of the world.
The specialty segment is the second largest and accounts for about 41% of the total revenue of Teva in 2013. The specialty segment focuses on areas including medicines for respiratory and CNS disorders, oncology and women’s health. CNS’s leading brand is Copaxone, in 2013, which generated $4.3 billion in sales, making up 21% of the company’s sales and constituting 42% of the company’s earnings.
The others segment accounts for 10% of sales. In this segment, Teva has built a unique relationship with P&G and operates in 65 markets outside North America, selling cough/cold and allergy, digestion, vitamins, minerals and supplements, and painkillers.
1.3 Current Situation and